These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25254090)

  • 1. Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia.
    Ghasemi A; Keikhaei B; Ghodsi R
    Iran J Ped Hematol Oncol; 2014; 4(3):114-7. PubMed ID: 25254090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
    Ballas SK; Connes P;
    Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
    Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
    Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
    Figueiredo L; Morrone K; Wei C; Ireland K; Cohen HW; Driscoll C; Manwani D
    Blood Cells Mol Dis; 2017 Jul; 66():19-23. PubMed ID: 28783617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A; Gumruk F; Gurgey A
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
    Karimi M; Darzi H; Yavarian M
    J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
    Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Haematological Effects of Hydroxyurea in β-Thalassemia Intermedia Patients.
    Keikhaei B; Yousefi H; Bahadoram M
    J Clin Diagn Res; 2015 Oct; 9(10):OM01-3. PubMed ID: 26557561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined and differential effects of alpha-thalassemia and HbF-quantitative trait loci in Senegalese hydroxyurea-free children with sickle cell anemia.
    Gueye Tall F; Martin C; Ndour EHM; Renoux C; Ly ID; Connes P; Gueye PM; Diallo RN; Diagne I; Diop PA; Cissé A; Lopez Sall P; Joly P
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27934. PubMed ID: 31322815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
    Dehury S; Purohit P; Patel S; Meher S; Kullu BK; Sahoo LK; Patel NK; Mohapatra AK; Das K; Patel DK
    Pediatr Blood Cancer; 2015 Jun; 62(6):1017-23. PubMed ID: 25546091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
    Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
    Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
    Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.